1
Home
Companies

Relmada Therapeutics

#10134

Rank

$19.75M

Marketcap

US United States

Country

Relmada Therapeutics
Leadership team

Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD (CEO & Director)

Mr. Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph. (Chief Financial Officer)

Mr. Charles S. Ence CPA, M.B.A. (Chief Accounting & Compliance Officer)

Products/ Services
Biotechnology, Clinical Trials, Pharmaceutical
Headquarters
New York, New York, United States
Established
2004
Company Registration
SEC CIK number: 0001553643
Traded as
RLMD
Social Media
URL
https://www.relmada.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
History

Relmada was founded in 2013 to develop novel, differentiated medicines for the treatment of serious chronic conditions. The company has established a clinical-stage product portfolio that includes differentiated products at various stages of development. The company is located in Newport Beach, California with staff in multiple states.

Mission
Our mission is to develop and commercialize innovative, novel and safe pharmaceuticals to the benefit of human healthcare.
Vision
Our vision is to build a leading specialty pharmaceutical company capable of achieving sustained success in the central nervous system therapy area.
Key Team

Dr. Paolo Manfredi M.D., Ph.D. (Chief Scientific Officer)

Ms. Gina DiGuglielmo (VP & Head of Clinical Operations)

Dr. Marco Pappagallo M.D. (Chief Medical Officer)

Dr. Richard M. Mangano (Consultant)

Mr. John Hixon (Head of Commercial)

Recognition and Awards
Relmada has received numerous awards over the years, including the 2015 OIVCE Certified Companies Program Award, the 2014 American Therapeutic Professional of the Year Award, and the 2017 World Regulatory Drugs Award.
References

https://in.investing.com/equities/relmada-therapeutics

https://finance.yahoo.com/quote/RLMD/profile?p=RLMD

https://www.crunchbase.com/organization/relmada-therapeutics

https://companiesmarketcap.com/

https://www.relmada.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Relmada Therapeutics
Leadership team

Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD (CEO & Director)

Mr. Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph. (Chief Financial Officer)

Mr. Charles S. Ence CPA, M.B.A. (Chief Accounting & Compliance Officer)

Products/ Services
Biotechnology, Clinical Trials, Pharmaceutical
Headquarters
New York, New York, United States
Established
2004
Company Registration
SEC CIK number: 0001553643
Traded as
RLMD
Social Media
URL
https://www.relmada.com